Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Markus Warmuth
- Employees
- 173
- Market cap
- $831 M
- IPO
- 24/06/2021
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader…
Monte Rosa Therapeutics stock: price history
1D
-3.8%
1W
-5.4%
1M
-23.0%
6M
-50.8%
YTD
-37.9%
1Y
-5.5%
2Y
+77.1%
5Y
-54.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% stronger price swings than usual
Ask the agents about Monte Rosa Therapeutics
Analyst assessment of Monte Rosa Therapeutics
PRICE TARGET LOW
US$19.00
CONSENSUS
US$24.83
MEDIAN
US$25.00
PRICE TARGET HIGH
US$28.00
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 05/10/2026
Monte Rosa Therapeutics stock metrics
P/E
-4.47
P/B
1.7
EV/EBITDA
-5
RETURN ON EQUITY
-8.9%
NET MARGIN
-483.9%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
70.5%
FLOAT SHARES
60,168,043
AVG. DAILY VOLUME (30D)
1,399,999
Insider transactions (SEC)
Bowen Matthew
Warmuth Markus
Champoux Jennifer
Champoux Jennifer
Townson Sharon
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Monte Rosa Therapeutics stock
What does Monte Rosa Therapeutics do?
Monte Rosa Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Markus Warmuth, the company employs around 173 people.
The IPO was on 24/06/2021; the stock trades on NASDAQ under the ticker GLUE.
What do analysts say about Monte Rosa Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$24.83, ranging from US$19.00 to US$28.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Monte Rosa Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Monte Rosa Therapeutics pay a dividend?
No, Monte Rosa Therapeutics currently does not pay a dividend.
Which stocks are comparable to Monte Rosa Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Monte Rosa Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Monte Rosa Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.